Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.
In this interview from our recent Institute for Value-Based Medicine® meeting in New York City on February 8, Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model (EOM) kicks off on July 1.
Transcript
What is the current state of value-based care in oncology, and what are some top priorities of the EOM that hope to improve upon the OCM?
We’re in this interesting, I call it almost an inflection point in value-based care in oncology. You have the Medicare models: OCM [Oncology Care Model], obviously, the large one, and then EOM coming, which is going to be much smaller, probably about half the patients. The devil is still going to be in the details. We’re still awaiting practice-specific baseline data to get a better understanding of how our practice, Tennessee Oncology, will do on that. We’re obviously very committed to value-based care but need to see the details.
But around that, things are changing. Medicare Advantage [MA] is blowing up. You saw the $10 billion Oak Street acquisition that just happened with CVS. All these risk-bearing entities that are not really touching oncology yet are growing up all around us, and what is the current oncology platforms’ play with that? The ones that are very invested in value-based care, they're gonna be new partnerships. And I'm not trying to speak ahead as if I know something that no one else knows, nothing like that. But you can imagine this ecosystem, where risk-based care is growing all around us—including the explosion of MA, which is capitated—and oncologists currently kind of in silo, understanding value-based care with OCM and all these medical homes. Ours is BlueCross, Astera has done a bundle with Horizon. So all these things happening and how does it come together one day.
That's what I'm excited about in value-based care. Over the next 5 years as these consolidated, value-based care, largely primary care companies that manage the entire population, how does cancer fall into that? That's where I think value-based care is really going to change over the next 2, 5 years, or even longer.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More